Description

Drug Classification:

Amlodipine as Besylate + Valsartan Tablets belong to the class of medications known as antihypertensive combinations. This combination therapy combines the benefits of calcium channel blockade (Amlodipine) and angiotensin II receptor blockade (Valsartan) to achieve optimal blood pressure control.

Formulations:

• Amlodipine as Besylate + Valsartan Tablets:
  • Strengths:
    • Amlodipine 5mg / Valsartan 80 mg
    • Amlodipine 5mg / Valsartan 160 mg
    • Amlodipine 10 mg / Valsartan 160 mg
  • Product Form: Oral tablets for convenient administration.
  • Packing Specifications: Packaged in blister packs containing 14 tablets each.

Indications:

Amlodipine as Besylate + Valsartan Tablets are indicated for:

• Treatment of hypertension (high blood pressure) in patients whose blood pressure is not adequately controlled on monotherapy.
• Reduction of cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy.

Usage:

• Amlodipine as Besylate + Valsartan Tablets should be taken orally once daily with or without food, as directed by a healthcare professional.
• It is essential to adhere to the prescribed dosage and administration regimen to achieve optimal blood pressure control and therapeutic outcomes.

Dosage:

• The recommended starting dose of Amlodipine as Besylate + Valsartan Tablets depends on the individual patient’s blood pressure and previous antihypertensive therapy.
• Dosage adjustment may be necessary based on the patient’s response and tolerability, with a maximum dose of Amlodipine 10 mg / Valsartan 160 mg once daily.

Pharmacokinetics:

• Amlodipine is well absorbed after oral administration, with peak plasma concentrations reached within 6 to 12 hours. It undergoes extensive hepatic metabolism, with approximately 90% of the drug eliminated in the urine as metabolites.
• Valsartan is also well absorbed after oral administration, with peak plasma concentrations reached within 2 to 4 hours. It undergoes hepatic metabolism and excretion in the feces and urine.
• The elimination half-lives of Amlodipine and Valsartan are approximately 30 to 50 hours and 6 to 9 hours, respectively, allowing for once-daily dosing.

Pharmacodynamics:

• Amlodipine exerts its therapeutic effects by selectively inhibiting calcium influx through voltage-sensitive L-type calcium channels in smooth muscle cells of blood vessels, leading to vasodilation and decreased peripheral vascular resistance.
• Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor, promoting vasodilation and reducing blood pressure.

Side Effects:

• Common side effects associated with Amlodipine as Besylate + Valsartan Tablets may include peripheral edema, headache, dizziness, flushing, and fatigue.
• Rare but serious adverse effects such as hypotension, hyperkalemia, and renal dysfunction may occur and require medical attention.
• Patients should be monitored regularly for blood pressure, electrolyte levels, and signs of peripheral edema during treatment with Amlodipine as Besylate + Valsartan Tablets.

Experience the combined benefits of Amlodipine and Valsartan for effective blood pressure management, exclusively from AIT Pharmaceuticals Division. For more information, please contact us. Your cardiovascular health is our priority, and we are committed to providing innovative solutions for optimal patient care.